Skip to main content
Caplight Logo









Exeliom Biosciences

Exeliom Biosciences

Private
DijonHealthcare & Life Scienceshttps://www.exeliombio.com/

Last Round

Series A

Extension

Oct 21, 2025

Total Funding Raised

$28.98M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Exeliom Biosciences is a biotechnology company that develops microbiome-based immunotherapies using single bacterial strain drug candidates to treat inflammatory bowel diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

microbiome therapylive biotherapeutic productLBPinnate immune modulatormicrobiome drugimmunotherapyinflammatory bowel diseaseIBDoncologyFaecalibacterium prausnitziiNOD2 pathwaygut microbiomebiotechclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exeliom Biosciences Comparables

Compare Exeliom Biosciences with similar companies based on industry and business-model similarity.

Exeliom Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Microbiotica
83%
MRM Health
80%
Vedanta Biosciences
77%

Exeliom Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 21, 2025
GrantMar 6, 2024
GrantNov 28, 2023
Series A ExtensionJul 3, 2023
GrantAug 3, 2020
Grant
Aug 12, 2019

Key People

Founding team and executive leadership

Benjamin Hadida

CEO Co-Founder

Founding Team

Mathilde Delaunay

Chief Operating Officer

Executive Team

Exeliom Biosciences Investors

Notable investors and investment history

Exeliom Biosciences investors
InvestorRounds
Forepont Capital PartnersSeries A Extension
CE-VenturesSeries A Extension
Sofimac InnovationSeries A
National Research Institute for Agriculture, Food and EnvironmentSeries A
Auriga PartnersSeries A Extension, Series A
Capital Grand EstSeries A Extension, Series A
Crohn's & Colitis FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 288% MoM to 1.3K.

  • Jul 10, 2025

    Announced the launch of LIVEDIFF Part 2.

Exeliom Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exeliom Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exeliom Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersDijon
Employee Range9
Year Founded2016
Last FundingOct 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?